CONSTRUCTS OF UNION
Patent Information
- Application Number
- ARP20250100434
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-30
- Filing Date
- 2025-02-17
- Publication Date
- 2026-08-05
Claims
The invention provides inter alia a construction comprising a FAP bonding agent and an LTBR bonding agent.
1. A construction comprising a FAP bonding agent and an LTBR bonding agent.
22. A binding polypeptide comprising or consisting of a heavy chain variable domain ((such as a VHH) that binds to LTBR wherein the heavy chain variable domain comprises or consists of three heavy chain complementarity determining regions (HCDR1 - HCDR3) and FR regions (14), wherein (a) HCDR 1 comprises or comprises a polypeptide sequence of SEQ ID No 60 or 172, HCDR 2 comprises or comprises a polypeptide sequence of SEQ ID No 61 or 173 and HCDR 3 comprises or comprises a polypeptide sequence of SEQ ID No 60 or 62 174; (b) HCDR 1 comprises or consists of a polypeptide sequence of SEQ ID No. 57 or 166, HCDR 2 comprises or consists of a polypeptide sequence of SEQ ID No. 58 or 167 and HCDR 3 comprises or consists of a polypeptide sequence of SEQ ID No. 59 or 168;(c) HCDR 1 comprises or comprises a polypeptide sequence of SEQ ID No 63 or 163, HCDR 2 comprises or comprises a polypeptide sequence of SEQ ID No 64 or 164 and HCDR 3 comprises or comprises a polypeptide sequence of SEQ ID No 63 or 65 165; (d) HCDR 1 comprises or comprises a polypeptide sequence of SEQ ID No 66 or 169, HCDR 2 comprises or comprises a polypeptide sequence of SEQ ID No 67 or 170 and HCDR 3 comprises or comprises a polypeptide sequence of SEQ ID No 66 or 68 171; (e) HCDR 1 comprises or consists of a polypeptide sequence of SEQ ID No. 163, HCDR 2 comprises or consists of a polypeptide sequence of SEQ ID No. 164 and HCDR 3 comprises or consists of a polypeptide sequence of SEQ ID No. 165;(f) HCDR 1 comprises or consists of a polypeptide sequence of SEQ ID NO: 166, HCDR 2 comprises or consists of a polypeptide sequence of SEQ ID NO: 167 and HCDR 3 comprises or consists of a polypeptide sequence of SEQ ID NO: 168; (g) HCDR 1 comprises or consists of a polypeptide sequence of SEQ ID NO: 169, HCDR 2 comprises or consists of a polypeptide sequence of SEQ ID NO: 170 and HCDR 3 comprises or consists of a polypeptide sequence of SEQ ID NO: 171; or (h) HCDR 1 comprises or consists of a polypeptide sequence of SEQ ID NO: 172, HCDR 2 comprises or consists of a polypeptide sequence of SEQ ID NO: 173, and HCDR 3 comprises or consists of a polypeptide sequence of SEQ ID NO:
174.
25. A construct or polypeptide of any of claims 1 to 24 for use in the treatment of cancer (e.g., a tumor) in combination with radiotherapy, a cancer vaccine, or ADC.